Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer

David R. Gandara, MD
Published: Thursday, Sep 07, 2017



David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses PD-L1 as a biomarker in lung cancer.

PD-L1 has had ups and downs as a biomarker, says Gandara. It seemed promising early on, but after data with nivolumab (Opdivo) came out in non-small cell lung cancer, it was no longer seen as a specific indicator.

Gandara adds that the field is still grasping for the best biomarkers to use in this disease.
 


David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses PD-L1 as a biomarker in lung cancer.

PD-L1 has had ups and downs as a biomarker, says Gandara. It seemed promising early on, but after data with nivolumab (Opdivo) came out in non-small cell lung cancer, it was no longer seen as a specific indicator.

Gandara adds that the field is still grasping for the best biomarkers to use in this disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x